ClinicalTrials.gg
CompletedNCT07937683Updated Nov 16, 2026

Comparison of Three Treatments for Myofascial Pain in Patients With Bruxism

An interventional study of Dry needling and Botulinium Toxin-A in Myofascial Pain - Dysfunction Syndrome of TMJ and Bruxism, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 6 months after the study started (first participant enrolled May 2021, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies in Temporomandibular Joint Disorders with a site in Turkey — 27 open to participants now, 28 under way, none of them phase 3. Temporomandibular Joint Disorders · Turkey.

Enrollment
8th of 81
90 · median 45
Started
2021
with 15 others
No phase
77 of 151
13 open now
Registered
151st of 151
by date

Among the 151 studies in Temporomandibular Joint Disorders with a site in Turkey, this one is the 8th largest by enrollment of the 81 interventional ones that give a count, is one of 16 that started in 2021, is one of 77 with no phase, and was the 151st registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

27 of the 151 studies in Temporomandibular Joint Disorders with a site in Turkey are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Temporomandibular Joint Disorders with a site in Turkey, or all of them as a file.
02

Study summary

This study compared three treatments for myofascial pain in adults with clinical features of bruxism, such as tooth clenching or grinding. Myofascial pain is pain arising from muscles and sensitive areas within them.

Ninety adults aged 18-60 years were randomly assigned to one of three groups: dry needling, botulinum toxin type A injections, or an occlusal splint worn at night together with medication. Dry needling involved inserting thin needles into sensitive points in the masseter muscles. Botulinum toxin injections were administered into the masseter muscles on both sides. The splint group received tizanidine and paracetamol for one month.

The study assessed pain at rest and during jaw function, sensitivity to pressure, and mouth opening. Assessments were performed before treatment and at one day, one week, and one month after treatment. The purpose was to compare the short-term effects of these three treatments.

03

Conditions studied

  • Myofascial Pain - Dysfunction Syndrome of TMJ
  • Bruxism

Keywords

  • Masseter Muscle
  • Botulinum Toxin Type A
  • Occlusal Splint
  • Dry Needling
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-60 years.
  • Bilateral myofascial pain diagnosed according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).
  • Self-reported and clinical features of bruxism, including tooth clenching and/or grinding, tooth wear or fractures, and increased masseter muscle tension.
  • (ASA) physical status I.
  • Written .

Exclusion criteria

Exclusion Criteria:

Intra-articular or degenerative temporomandibular disorders.

  • Pregnancy.
  • Gastrointestinal, hepatic, renal, or psychiatric conditions that could interfere with the planned treatment.
  • Treatment for temporomandibular disorders within the preceding three months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Dry Needling

    Thirty participants received a single session of dry needling targeting two or three active trigger points in each masseter muscle bilaterally. Sterile, single-use acupuncture needles (0.25 × 25 mm) were inserted approximately 5 mm deep, briefly manipulated, and retained for 20 minutes.

    Procedure: Dry needling

  • Experimental
    Occlusal Splint With Adjunctive Pharmacotherapy

    Thirty participants received a custom-made maxillary occlusal splint combined with medication for one month. Splints were fabricated from 3-mm-thick polyvinyl acetate-polyethylene copolymer sheets using a vacuum-forming technique and individually fitted and adjusted. Participants were instructed to wear the splint every night for one month and take oral tizanidine 2 mg every 12 hours and paracetamol 500 mg every 12 hours for the same period.

    Device: Occlusal Splint · Drug: TiZANidine 2 MG Oral Capsule · Drug: Paracetamol (500 mg) tablets

  • Experimental
    Botulinum Toxin Type A

    Thirty participants received a single session of botulinum toxin type A injections into both masseter muscles. A 100-unit vial was reconstituted with 2.5 mL of sterile 0.9% saline. Each masseter received 20 units distributed across three injection sites, for a total dose of 40 units per participant. Injections were administered with the needle inserted at approximately 45 degrees to the skin surface.

    Drug: Botulinium Toxin-A

Interventions

  • ProcedureDry needling

    A single session of bilateral masseter dry needling was performed, targeting two or three active trigger points per muscle. Sterile, single-use acupuncture needles measuring 0.25 × 25 mm were inserted approximately 5 mm deep. Needles were briefly manipulated using rapid in-and-out movements and redirected within the trigger point region, then retained for 20 minutes.

  • DrugBotulinium Toxin-A

    Botulinum toxin type A (Botox, Allergan) was administered into both masseter muscles during a single session. A 100-unit vial was reconstituted with 2.5 mL of sterile 0.9% saline. Each masseter received 20 units distributed across three injection sites, for a total dose of 40 units per participant. The needle was inserted at approximately 45 degrees to the skin surface.

  • DeviceOcclusal Splint

    A custom-made maxillary occlusal splint was fabricated from a 3-mm-thick polyvinyl acetate-polyethylene copolymer sheet using a vacuum-forming technique. Each splint was individually fitted and adjusted intraorally. Participants were instructed to wear the splint every night for one month.

  • DrugTiZANidine 2 MG Oral Capsule

    Tizanidine 2 mg was administered orally every 12 hours for one month as adjunctive pharmacotherapy in the occlusal splint group.

  • DrugParacetamol (500 mg) tablets

    Paracetamol 500 mg was administered orally every 12 hours for one month as adjunctive pharmacotherapy in the occlusal splint group.

06

What researchers measure

Primary outcomes

  1. Pain Intensity at Rest

    Pain intensity at rest was assessed using a 0-10 visual analog scale (VAS), where 0 indicated no pain and 10 indicated the worst imaginable pain. Lower scores indicate less pain.

    Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.

  2. Pain Intensity During Function

    Pain intensity during jaw function was assessed using a 0-10 visual analog scale (VAS), where 0 indicated no pain and 10 indicated the worst imaginable pain. Lower scores indicate less pain.

    Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.

Secondary outcomes

  1. Pressure Pain Threshold

    Pressure pain threshold was measured in kg/cm² using a pressure algometer over the identified masseter trigger point. Pressure was applied perpendicular to the skin and increased at approximately 1 kg/cm² per second until pressure first became painful. Higher values indicate a higher pressure pain threshold.

    Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.

  2. Maximum Pain-Free Mouth Opening

    Maximum pain-free mouth opening was measured as the interincisal distance in millimeters using a millimetric ruler. Participants opened their mouth until pain was first perceived. Greater distances indicate greater pain-free mouth opening.

    Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.

  3. Maximum Mouth Opening With Pain

    Maximum mouth opening with pain was measured as the interincisal distance in millimeters using a millimetric ruler. Participants opened their mouth as far as possible despite the onset of pain. Greater distances indicate greater maximum mouth opening.

    Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.

07

Study locations

1 site
  • Department of Oral and Maxillofacial Surgery, Gülhane Faculty of Dentistry, University of Health Sciences
    Ankara, Ankara 06790, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — There is currently no plan to share individual participant data with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Oct 2022, 17 months.

Of 242 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's 17 months is above that.

Counting every sponsor, half of 246 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
May 1, 2021
Primary completionActual
Oct 14, 2022
CompletionActual
Oct 14, 2022
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937683
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
May 1, 2021
Primary completion
Oct 14, 2022
Completion
Oct 14, 2022
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion